key: cord-0788637-wrz348e1
authors: Storey, Nathaniel; Brown, Julianne R; Pereira, Rui P A; O'Sullivan, Denise M; Huggett, Jim F; Williams, Rachel; Breuer, Judith; Harris, Kathryn A
title: Single base mutations in the nucleocapsid gene of SARS-CoV-2 affects amplification efficiency of sequence variants and may lead to assay failure
date: 2021-08-15
journal: Journal of clinical virology plus
DOI: 10.1016/j.jcvp.2021.100037
sha: 22a7d78efd6b73c9cf193f1fc3afb73fd2663eed
doc_id: 788637
cord_uid: wrz348e1

Reverse transcriptase quantitative PCR (RT-qPCR) is the main diagnostic assay used to detect SARS-CoV-2 RNA in respiratory samples. RT-qPCR is performed by specifically targeting the viral genome using complementary oligonucleotides called primers and probes. This approach relies on prior knowledge of the genetic sequence of the target. Viral genetic variants with changes to the primer/probe binding region may reduce the performance of PCR assays and have the potential to cause assay failure. In this work we demonstrate how two single nucleotide variants (SNVs) altered the amplification curve of a diagnostic PCR targeting the Nucleocapsid (N) gene and illustrate how threshold setting can lead to false-negative results even where the variant sequence is amplified. We also describe how in silico analysis of SARS-CoV-2 genome sequences available in the COVID-19 Genomics UK Consortium (COG-UK) and GISAID databases was performed to predict the impact of sequence variation on the performance of 22 published PCR assays. The vast majority of published primer and probe sequences contain sequence mismatches with at least one SARS-CoV-2 lineage. We recommend that visual observation of amplification curves is included as part of laboratory quality procedures, even in high throughput settings where thresholds are set automatically and that in silico analysis is used to monitor the potential impact of new variants on established assays. Ideally comprehensive in silico analysis should be applied to guide selection of highly conserved genomic regions to target with future SARS-CoV-2 PCR assays.

sequence of the target. Viral genetic variants with changes to the primer/probe 23 binding region may reduce the performance of PCR assays and have the potential to 24 cause assay failure. In this work we demonstrate how two single nucleotide variants 25 (SNVs) altered the amplification curve of a diagnostic PCR targeting the 26 Nucleocapsid (N) gene and illustrate how threshold setting can lead to false-negative 27 results even where the variant sequence is amplified. We also describe how in silico 28 analysis of SARS-CoV-2 genome sequences available in the COVID-19 Genomics UK 29 Consortium (COG-UK) and GISAID databases was performed to predict the impact of 30 sequence variation on the performance of 22 published PCR assays. The vast 31 majority of published primer and probe sequences contain sequence mismatches 32 with at least one SARS-CoV-2 lineage. We recommend that visual observation of 33 amplification curves is included as part of laboratory quality procedures, even in high 34 throughput settings where thresholds are set automatically and that in silico analysis 35 is used to monitor the potential impact of new variants on established assays. Ideally 36 comprehensive in silico analysis should be applied to guide selection of highly 37 conserved genomic regions to target with future SARS-CoV-2 PCR assays.

The SARS-CoV-2 pandemic required rapid implementation of diagnostic testing. The 45 only method capable of meeting this need was reverse transcriptase quantitative 46 PCR (RT-qPCR) which worked by detecting SARS-CoV-2 RNA. Reliable RT-qPCR assays 47 played an important role in guiding patient management and limiting the onward 48 transmission of SARS-CoV-2 [1]. Diagnostic laboratories across the world are 49 currently using a wide variety of different commercial and locally developed assays that target a range of SARS-CoV-2 genes. 51 52 SARS-CoV-2 genetic variants exist that have the potential to lead to phenotypic 53 changes manifesting as differences in viral infectivity, burden, immunogenicity and 54 tropism during the course of infection [2] [3] [4] [5] [6] [7] [8] . Genetic variants form a natural part of 55 infection as SARS-CoV-2, a zoonotic virus, evolves with its new human host and can 56 become established in the population. Variants of concern (VOC) are variants of 57 SARS-CoV-2 that may be more infectious, cause more severe disease or lead to 58 vaccine or immunological escape [9] . Consequently accurate and rapid detection of 59 VOCs is important to manage a pandemic. RT-qPCR is performed by using short DNA 60 molecules (primers and probes) that complement and directly bind the SARS-CoV-2 61 genome, therefore genetic variants may affect assay performance. An emerging 62 sequence variant could escape detection in molecular assays. This may be an 63 infrequent event, but if it occurs the impact could be very significant. Individuals 64 could be incorrectly told they are not infected, potentially increasing the spread of a 65 new variant. This is even more challenging during the SARS-CoV-2 pandemic, as new 66 sequence variants arise frequently [10, 11] . Consequently it is important that 67 diagnostic developers and those applying RT-qPCR for SARS-CoV-2 diagnosis are 68 aware of the potential impact of VOCs on their assays both in terms of surveillance 69 and RT-qPCR output . In this report we investigate how sequencing can be used locally to determine the 72 sequence lineages of 332 consecutive samples that were SARS-CoV-2 PCR positive in 73 our laboratory between 26 th March 2020 and 17 th December 2020. We also explored 74 the effect two single-nucleotide variants (SNVs) have on the performance of an RT-75 qPCR diagnostic PCR assay and if different analysis parameters (such as threshold 76 setting or applying Cq cut offs) can lead to different results. We then use this 77 sequence data to perform in silico analysis of primer and probe sequences from 22 78 published SARS-CoV-2 PCR assays to predict potential impact of VOCs on these 79 approaches and make recommendations for a proactive and standardised approach 80 to assay design and monitoring. infected with variants of concern, with high viral burden, could potentially be told tools and how to assess the impact of sequence variation on assay performance. 303 The in silico analysis we present here could be broadened to include all lineages 304 circulating locally and also any other global lineages of interest in GISAID [19] . The 305 availability of SARS-CoV-2 sequence data in the UK provides an excellent opportunity 306 to perform surveillance of sequence data and to pre-empt the impact of any 307 variation on diagnostic tests. We propose that a standardised approach should be 308 adopted to continuously monitor the impact of sequence variants on diagnostic tests 309 before they become prevalent in the community and guide the selection of highly 310 conserved regions of the SARS-CoV-2 genome to use as PCR targets to improve 311 diagnostic tests in the future. 

Diagnostic testing for SARS-CoV-2. 2020, World Health 335 Organisation

Mortality in COVID-19 disease patients: Correlating the association of 337 major histocompatibility complex (MHC) with severe acute respiratory syndrome

CoV-2) variants

Are the emerging SARS-COV-2 mutations friend or foe?

The SARS-CoV-2 ORF10 is not essential in vitro or in vivo in humans

Neutralization of SARS-CoV-2 spike 69/70 deletion, E484K and N501Y variants 344 by BNT162b2 vaccine-elicited sera

South African 346 (501Y.V2) SARS-CoV-2 Variants with a Focus at the ACE2-Spike RBD Interface

Effects of a major deletion in the SARS-CoV-2 genome on the severity of 349 infection and the inflammatory response: an observational cohort study. The Lancet

SARS-CoV-2 spike-protein D614G mutation increases virion spike density and 352 infectivity

Updated rapid risk assessment from ECDC on the risk related to the spread of new 356 SARS-CoV-2 variants of concern in the EU/EEA -first update

Rampant C-->U Hypermutation in the Genomes of SARS-CoV-2 and Other 359 Coronaviruses: Causes and Consequences for Their Short-and Long-Term Evolutionary 360 Trajectories. mSphere

Comparison of SARS-CoV2 N gene real-time RT-PCR targets and 362 commercially available mastermixes

Extraction-free COVID-19 (SARS-CoV-2) diagnosis by RT-PCR to increase 364 capacity for national testing programmes during a pandemic. bioRxiv

SARS-CoV-2 genomes recovered by long amplicon tiling multiplex 367 approach using 368 nanopore sequencing and applicable to other sequencing platforms

Improvements to the ARTIC multiplex PCR method for SARS-CoV-2 genome 370 sequencing using nanopore

COVID-19 ARTIC v3 Illumina library construction and sequencing protocol 372

ARTIC-nCoV-bioinformaticsSOP-v1.1.0. 2020

Data, disease and diplomacy: GISAID's innovative 378 contribution to global health. Glob Chall

The Sequence Alignment/Map format and SAMtools

Fast, scalable generation of high-quality protein multiple sequence 382 alignments using Clustal Omega

Phylogenetic Assignment of Named Global Outbreak 384

Clinical Characteristics of 138 Hospitalized Patients With

Coronavirus-Infected Pneumonia in Wuhan, China. JAMA

Detection of 2019 novel coronavirus (2019-nCoV) by real-time RT-PCR. 388 Euro surveillance : bulletin Europeen sur les maladies transmissibles = European 389 communicable disease bulletin

Temporal profiles of viral load in posterior oropharyngeal saliva samples 393 and serum antibody responses during infection by SARS-CoV-2: an observational cohort 394 study. The Lancet. Infectious diseases

A familial cluster of pneumonia associated with the 2019 novel 396 coronavirus indicating person-to-person transmission: a study of a family cluster. The Lancet

Genomic characterisation and epidemiology of 2019 novel coronavirus: 399 implications for virus origins and receptor binding. The Lancet

A Recurrent Mutation at Position 26340 of SARS-CoV-2 Is Associated with 401 Failure of the E Gene Quantitative Reverse Transcription-PCR

A novel point mutation in the N gene of SARS-CoV-2 may affect the 404 detection of the virus by RT-qPCR

Primer design for quantitative real-time PCR for the emerging 406

Use of Whole Genome Sequencing Data for a First in Silico Specificity 408 Evaluation of the RT-qPCR Assays Used for SARS-CoV-2 Detection

Appendix: Full list of primer and probe sequenced from published assays used in this 414 analysis. Available from WHO website: 415 https://www.who.int/publications/m/item/molecular-assays-to-diagnose-covid-19- 416 summary-